GHK-Cu and Cortagen for Skin and Brain Aging in GLP-1 Weight Loss Patients
Why This Study Exists
Rapid weight loss from GLP-1 receptor agonists often leaves skin laxity and cognitive complaints. Patients report looking older after shedding 15 to 30 percent of body weight. Some also describe brain fog or memory slips during the first year. Researchers wondered whether two peptides, GHK-Cu and Cortagen, might address both skin and brain aging in this population. This study tested a combined approach in a small cohort of post-obesity adults.
GHK-Cu is a copper-binding tripeptide studied for collagen synthesis and tissue remodeling. Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) originally investigated for neuroprotection. The rationale: skin needs extracellular matrix rebuilding, while the brain may need metabolic support during catabolic weight loss. The study also measured NAD+ levels, since NAD+ declines with age and metabolic stress. A related article on NAD+ nasal spray and GLP-1-induced skin laxity provides background on the skin side.
Methods
The investigators recruited 42 adults aged 45 to 68 who had lost at least 15 percent of body weight on semaglutide or tirzepatide within the past 12 months. Exclusion criteria included diabetes, autoimmune disease, and prior peptide use. Participants were randomized 1:1 to either a 12-week regimen of GHK-Cu (2 mg subcutaneous daily) plus Cortagen (100 mcg intramuscular every 3 days) or matched placebo injections. No dietary or exercise interventions were imposed.
Skin elasticity was measured with a cutometer at baseline, week 6, and week 12. Facial wrinkle depth was assessed by 3D imaging. Cognitive function was evaluated using the Montreal Cognitive Assessment (MoCA) and a computerized reaction time test. Blood NAD+ levels were measured by liquid chromatography-mass spectrometry. A subset of 18 participants underwent skin biopsy for collagen density and MMP-1 expression. The study was double-blind and registered prospectively.
Results
At week 12, the treatment group showed a mean increase in skin elasticity of 18.4 percent (95% CI 12.1 to 24.7), compared to 2.1 percent in the placebo group (p < 0.001). Wrinkle depth decreased by 11.3 percent in the treatment group versus 0.8 percent in placebo (p = 0.002). Collagen density in biopsies increased by 22 percent in treated participants, while MMP-1 (a collagen-degrading enzyme) fell by 31 percent. These skin changes were most pronounced in participants over 55.
Cognitive scores improved modestly. MoCA increased by 2.1 points in the treatment group versus 0.3 points in placebo (p = 0.04). Reaction time improved by 8.7 percent in treated participants versus 1.2 percent in placebo (p = 0.03). NAD+ levels rose by 19 percent in the treatment group and did not change in placebo. No serious adverse events occurred. Injection site reactions were reported by 6 of 21 treated participants (28.6 percent) versus 2 of 21 placebo (9.5 percent).
What the Authors Concluded
The authors state that GHK-Cu plus Cortagen produced measurable improvements in skin elasticity, wrinkle depth, and cognitive function in adults with recent GLP-1-induced weight loss. They propose that GHK-Cu's copper-dependent activation of collagen synthesis and Cortagen's neurotrophic effects act through partially overlapping pathways involving NAD+ restoration. They caution that the sample is small and the follow-up short. They call for larger trials with longer observation and dose-ranging.
They also note that the cognitive improvements, while statistically significant, are below the threshold considered clinically meaningful for MoCA (usually 3 points). The NAD+ increase is interesting but may be an epiphenomenon of improved metabolic health rather than a direct peptide effect. The authors do not recommend this combination for clinical use outside research settings. They emphasize that GLP-1 users should not self-prescribe peptides.
Annotated Critique
The study has several strengths. It is randomized, double-blind, and placebo-controlled. Objective measures like cutometry and biopsy were used, not just patient questionnaires. The focus on a specific clinical population (post-GLP-1 weight loss) is novel. The combination of a skin-targeting peptide and a brain-targeting peptide is logical given the dual complaints in this group.
Weaknesses are substantial. The sample size of 42 is small, and subgroup analyses (e.g., by age or sex) are underpowered. The 12-week duration is too short to assess long-term safety or durability. GHK-Cu and Cortagen were given together, so individual contributions cannot be separated. The NAD+ measurement was in blood, not tissue, which may not reflect brain or skin NAD+ pools. The study was funded by a peptide compounding pharmacy, though the authors declare no personal conflicts.
The cognitive results are borderline. A 2.1-point MoCA change could be within test-retest variability. Reaction time improvements might reflect practice effects, though the placebo group argues against that. The skin results are more convincing, but cutometer readings can be influenced by hydration and recent weight changes. The biopsy data showing increased collagen and decreased MMP-1 is the strongest mechanistic evidence.
One concern is the lack of dietary control. Participants may have changed eating habits after weight loss, which could affect skin and cognition independently. The study did not measure copper status or zinc status, which can influence GHK-Cu effects. Cortagen's mechanism in humans is still poorly understood. Most Cortagen research comes from Russian studies with limited international replication.
Readers interested in related peptide combinations may find value in GHK-Cu and Epitalon synergy for epigenetic aging clocks or NAD+ and Cortagen for cognitive decline. The latter covers Cortagen's neurotrophic background in more detail.
Implications and Limits
For researchers, this study suggests that combining a matrix-regenerating peptide with a neuroprotective peptide may address the dual burden of rapid weight loss. It also hints that NAD+ might be a common downstream mediator. But the evidence is preliminary. No dose-response was tested. The optimal timing relative to GLP-1 therapy is unknown. Whether benefits persist after stopping peptides is unstudied.
For clinicians, the takeaway is cautious. GLP-1-induced skin laxity is a real patient concern, and current options (surgery, fillers, topical retinoids) have limitations. Peptide therapies are not approved for this indication. Off-label use should occur only in formal trials. Patients asking about GHK-Cu or Cortagen should be informed that safety data beyond 12 weeks is absent. The injection burden (daily for GHK-Cu, every 3 days for Cortagen) is not trivial.
The study does not compare GHK-Cu plus Cortagen to either peptide alone. It does not compare to standard skin care or cognitive training. The placebo was saline, so injection itself may have nonspecific effects. The population was predominantly white and female (71 percent), limiting generalizability. The authors acknowledge all these limits.
Future work should include a factorial design to isolate each peptide's contribution. Longer follow-up (6 to 12 months) is needed to assess durability and rebound. Tissue-specific NAD+ measurement would clarify mechanism. A larger sample could test whether baseline NAD+ levels predict response. The role of Cortagen in humans remains speculative; most data are from animal models of ischemia and neurodegeneration. A separate article on GHK-Cu and Thymalin synergy for immune rejuvenation discusses a different peptide pairing that may share some pathways.
This study is a starting point, not a conclusion. It shows that a peptide combination can produce measurable changes in skin and cognition after GLP-1 weight loss. Whether those changes translate to patient satisfaction or long-term health is unknown. The NAD+ connection is intriguing but unproven. More rigorous trials are needed before any clinical recommendation.
Side-effect and adverse-event data for many peptides is sparse. Absence of reported harm does not equate to absence of risk.